Biotech Weekly Recap 2
Welcome to our Evergrowth Biotech Weekly Recap!
Big news this week:
● Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion! This deal strengthens their neuroscience portfolio with CAPLYTA, a game-changer for patients afflicted by schizophrenia and bipolar depression.
● Next, FDA reviews for several companies are underway with PDUFA target action date expected within this month. The FDA is reviewing promising treatments for early Alzheimer’s disease, breast cancer and pain therapies.
Click the link below for the full video and subscribe for weekly biotech insights! Stay tuned for next week’s updates on biotech breakthroughs! You might find a potential big winner. Don’t forget to like, comment, and subscribe for more cutting-edge updates!
#EvergrowthBiotech #BiotechRecap #JohnsonAndJohnson #IntraCellularTherapies #CAPLYTA #Schizophrenia #BipolarDepression #FDAReview #PDUFA #AlzheimersDisease #BreastCancer #PainTherapy #BiotechBreakthroughs #BiotechNews #PharmaUpdates #BiotechInsights #BiotechInvesting #PharmaceuticalNews #HealthcareInnovation #Biotechnology
▶ SCHEDULE A CALL WITH DR. TRAN:
https://calendly.com/drharveytran/eve...
▶ CONNECT WITH US:
Website: https://evergrowthinvest.com/
Email: [email protected]
LinkedIn: / evergrowth-biohealthcare-capital
Phone: +1(704) 957-7746
▶ CONNECT WITH DR. HARVEY TRAN:
Twitter: / drtranbiosci
LinkedIn: / drharveytran
Email: [email protected]
Disclaimer: As a medical doctor/market expert, I’m not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I am also NOT responsible for the actions of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investment in stocks and options can result in a loss of capital. The information presented should NOT be construed as a recommendation to buy or sell any form of security. My articles and videos are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your actions. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, what I shared with you is not professional medical advice. I simply share with you what I share with my own family to help get more out of your life.